How Glutamate May Trigger CGRP Release in Migraine — and Why Targeting Both Could Help More Patients

The review synthesizes evidence that glutamate acts as an upstream trigger for CGRP release in the trigeminovascular system. Elevated glutamate levels contribute to both peripheral sensitization (nerve activation around blood vessels) and central sensitization (amplified pain processing in the brain), potentially driving the transition from episodic to chronic migraine. The CGRP-glutamate relationship is bidirectional, with CGRP also capable of enhancing glutamate signaling, creating a feedforward loop that perpetuates migraine.

This is a narrative review examining the scientific literature on CGRP and glutamate interactions in migraine pathophysiology, covering evidence from preclinical studies, neuroimaging, and clinical observations. The review integrates findings on peripheral excitation, central sensitization, and therapeutic implications.

About one-third of migraine patients don't respond to CGRP-targeting therapies — the most important advance in migraine treatment in decades. Understanding that glutamate may be the upstream driver of CGRP release explains why blocking CGRP alone isn't always sufficient. This points to glutamate-targeting strategies as a complementary or alternative approach, potentially expanding effective treatment options for treatment-resistant migraine patients.

The migraine field has been dominated by CGRP for the past decade, with multiple antibodies and small molecules approved. This review redirects attention to glutamate — the brain's primary excitatory neurotransmitter — as a potentially more fundamental target. If the glutamate-CGRP axis can be disrupted at the glutamate level, it could prevent not just the CGRP-mediated component but also other downstream effects of excessive glutamate that contribute to migraine and central sensitization. This could reshape the next wave of migraine drug development.

As a narrative review, this does not include systematic methodology or meta-analysis. The glutamate-CGRP interaction model is largely based on preclinical data and has not been fully validated in clinical trials targeting glutamate for migraine. The complexity of glutamate signaling (essential for normal brain function) makes targeting it therapeutically challenging without side effects.